| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ae10212794160b34478f0d05b6ab6fd7 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-724
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-724
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2001-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b4b65d1611206c8b5dd8443583663c64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fb3dd4882892d04478e8eedbc606f50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4cb0d2bfaef77a63b3757995897fce3 |
| publicationDate |
2004-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
NZ-522767-A |
| titleOfInvention |
Thalidomide and a topoisomerase inhibitor for the treatment of cancer |
| abstract |
A topoisomerase inhibitor, preferably SN-38 and thalidomide are used in synergistic amounts for the manufacture of a composition or kit for treating primary or metastatic cancer, preferably colon or rectal cancer, for increasing the safe and effective dosage of the topoisomerase inhibitor by reducing a dose-limiting adverse effect associated with the inhibitor or for increasing the therapeutic efficacy of the topoisomerase, with the proviso that the inhibitor is not irinotecan. Thalidomide is also used in the manufacture of a composition for reducing or preventing an adverse effect associated with the chemotherapy or radiation therapy, with the proviso that the adverse effect is not due irinotecan or for protecting a cancer patient from adverse effects associated with the administration of an anti-cancer drug. Also described are pharmaceutical compositions and dosage forms comprising synergistic amounts of thalidomide and a topoisomerase inhibitor. |
| priorityDate |
2000-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |